PLIANT THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $1.6M | $9.7M | $7.6M | $41.8M | $57.1M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $109.2M | $169.3M | $127.8M | $96.9M | $77.5M | $66.2M | $47.4M |
| SG&A Expense | — | $47.2M | $59.1M | $57.9M | $39.9M | $27.6M | $17.3M | $10.9M |
| Operating Income | — | $-156.4M | $-228.4M | $-184.1M | $-127.2M | $-97.5M | $-41.6M | $-1.2M |
| Operating Margin | — | — | — | -11,654.7% | -1,313.4% | -1,288.1% | -99.6% | -2.2% |
| Interest Expense | — | — | — | $1.3M | $791.0K | $0 | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-149.3M | $-210.3M | $-161.3M | $-123.3M | $-97.3M | $-41.5M | $-631.0K |
| Net Margin | — | — | — | -10,211.1% | -1,273.3% | -1,284.5% | -99.3% | -1.1% |
| EPS (Basic) | — | $-2.43 | $-3.47 | $-2.75 | $-2.94 | $-2.71 | $-1.95 | $-0.32 |
| EPS (Diluted) | — | $-2.43 | $-3.47 | $-2.75 | $-2.94 | $-2.71 | $-1.95 | $-0.32 |
| Shares Outstanding (Basic) | 61.9M | 61.4M | 60.5M | 58.7M | 42.0M | 35.8M | 21.3M | 21.1M |
| Shares Outstanding (Diluted) | 61.9M | 61.4M | 60.5M | 58.7M | 42.0M | 35.8M | 21.3M | 21.1M |
| Dividends Per Share | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |